Parabulbar betamethasone shows rapid relief of diplopia in myasthenia gravis, suggesting new therapeutic options.
Parabulbar betamethasone provided rapid and durable relief of isolated, treatment‐resistant diplopia in seronegative myasthenia gravis after multiple systemic therapy failures, suggesting that targeted periocular corticosteroid delivery may be a steroid‐sparing option for carefully selected patients when standard treatments are ineffective and close ophthalmic monitoring is available.
No takes yet. Share an insight, caveat, or question.
Marchuk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: